Could a pill replace chemo for some breast cancers?

NCT ID NCT06107673

Recruiting now Disease control Sponsor: Hebei Medical University Fourth Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial compares a daily pill (dalpiciclib) plus hormone therapy against standard chemotherapy for postmenopausal women with a specific type of breast cancer (ER+ HER2-). The goal is to see if the pill combination works as well as chemo but with fewer side effects. About 144 participants will be enrolled across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dalpiciclib (a targeted cancer pill) plus an aromatase inhibitor (hormone therapy)
What this could lead to: If successful, this could offer a less toxic, pill-based alternative to chemotherapy for certain postmenopausal breast cancer patients.
What could go wrong: This is a small, early phase II trial, so results may not confirm non-inferiority or translate to broader populations. Side effects from the drug combination are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

The Fourth Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, 050011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.